key: cord-0997913-z7llrlwj
authors: Wang, Jue; Pendurthi, Usha R.; Yi, Guohua; Rao, L. Vijaya Mohan
title: SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase
date: 2021-06-03
journal: Blood
DOI: 10.1182/blood.2021010685
sha: 74e42275d69ae1e25e87c776bf68afdcad11aefc
doc_id: 997913
cord_uid: z7llrlwj

SARS-CoV-2 infection is associated with the hypercoagulable state. Tissue factor (TF) is the primary cellular initiator of coagulation. Most of the TF expressed on cell surfaces remains cryptic. Sphingomyelin (SM) is responsible for maintaining TF in the encrypted state, and hydrolysis of SM by acid sphingomyelinase (ASMase) increases TF activity. ASMase was shown to play a role in virus infection biology. In the present study, we investigated the role of ASMase in SARS-CoV-2 infection-induced TF procoagulant activity. Infection of human monocyte-derived macrophages (MDMs) with SARs-CoV-2 spike protein pseudovirus (SARS-CoV-2-SP-PV) markedly increased TF procoagulant activity at the cell surface and released TF+ extracellular vesicles (EVs). The pseudovirus infection did not increase either TF protein expression or phosphatidylserine externalization. SARS-CoV-2-SP-PV infection induced the translocation of ASMase to the outer leaflet of the plasma membrane, which led to the hydrolysis of SM in the membrane. Pharmacological inhibitors or genetic silencing of ASMase attenuated SARS-CoV-2-SP-PV-induced increased TF activity. Inhibition of SARS-CoV-2 receptor, angiotensin-converting enzyme-2, attenuated SARS-CoV-2-SP-PV-induced increased TF activity. Overall, our data suggest that SARS-CoV-2 infection activates the coagulation by decrypting TF through activation of ASMase. Our data suggest that the FDA-approved functional inhibitors of ASMase may help treat hypercoagulability in COVID-19 patients.

Although respiratory dysfunction is the primary feature of the COVID-19, many studies showed that a hypercoagulability state is frequently present in COVID-19 patients. 1, 2 Thromboembolic complications play a crucial role in the pathogenesis and mortality of COVID-19. 3, 4 Aberrant expression of tissue factor (TF) is associated with many forms of thrombosis. 5 Recent reviews suggest that TF may play a central role in thrombosis in COVID-19 patients. 6, 7 Increased expression of TF was found in platelet-monocyte aggregates from critically ill COVID-19 patients. 8 Skendros et al. 9 showed the expression of TF in neutrophils of severe COVID-19 patients. However, in the above studies, TF expression analyses were limited to microscopy, flow cytometry, or mRNA levels. Recently, Rosell et al. 10 reported that levels of extracellular vesicle (EV) TF activity were significantly higher in COVID-19 patients than control subjects, and the levels of EV TF activity were associated with disease severity and mortality. Interestingly, in contrast to the above studies, Mast et al. reported no increase in TF mRNA transcript in bronchoalveolar lavage fluids of COVID-19 patients. 11 TF expressed on cells, either constitutively or induced, possess very low or no procoagulant activity. 12 TF has to undergo post-translational modifications, commonly referred to as "decryption" or "activation," to exhibit optimal TF procoagulant activity. 12 Our recent studies showed that high sphingomyelin (SM) content in the outer leaflet of plasma membrane maintains TF in an encrypted state, and the hydrolysis of SM induced by pathophysiologic stimuli leads to TF activation. 13, 14 The breakdown of SM in the plasma membrane also leads to the generation of EVs. 13, 14 Many stimuli, including viral infections, can release sphingomyelinases, such as acid sphingomyelinase (ASMase), that can breakdown SM in the plasma membrane. 15 Recent studies suggest that ASMase plays a role in the infectivity of SARS-CoV-2. 16 Here, we investigated the role of ASMase in SARS-CoV-2 infection-induced TF-mediated coagulation.

293 T cells (1 × 10 7 cells) were transfected with 20 μg of vector plasmid pLVX-IRES-ZsGreen (Takara Bio), 16 μg of packaging plasmid psPAX2 (Addgene), and 10 μg of envelope plasmid pCAGGS-SARS-CoV-2 spike (obtained from BEI resources) using polyethyleneimine (Polysciences, Warrington, PA). After 30 min of transfection, DMEM supplemented with 10% FBS and antibiotics was added to the cells, and the cells were cultured at 37°C under 5% CO 2 . After 48-72 h, the supernatants were collected, filtered, and centrifuged at 25,000xg for 2.5 h at 4°C to sediment the pseudovirus particles. The pseudovirus pellet was resuspended in PBS, and the viral titers were determined by infecting a human lung cell line, H441, with serially diluted pseudovirus preparations.

The IRB at the University of Texas Health Science Center at Tyler approved the protocol to obtain blood from healthy volunteers. Human peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation, and monocytes are differentiated into macrophages, as described earlier. 13, 14 EVs from cell supernatants were isolated by centrifugation at 21, 000 x g for 1 h and quantified by nanoparticle tracking analysis as described recently. 13, 17 Measurement of TF activity TF activity on cell surfaces and EVs was measured as its ability to support the activation of factor X (FX) upon the addition of FVIIa and FX. 13, 14 Immunofluorescence microscopy and image acquisition Immunofluorescence labeling of TF, ASMase, and SM in MDMs, immunofluorescence confocal microscopy, and image acquisition were performed essentially as described in our earlier publications. 13, 14 

Macrophages were transfected with a control transfection reagent (mock transfection), scrambled oligonucleotide (scRNA), or siRNA specific for ASMase (100 nM) or ACE-2 (100 nM) using X-tremeGene TM transfection reagent (Sigma Aldrich, St. Louis, MO).

Infection of MDMs with SARS-CoV-2-SP-PV (0.6 MOI) led to a marked increase in cell surface TF activity in a time-dependent manner. The increased cell surface TF activity was evident as early as 5 to 15 min following the infection, but markedly higher at 6 h following the infection (Fig.1A) . SARS-CoV-2-SP-PV infection also increased TF activity associated with EVs, but the increase plateaued after 30 min (Fig. 1A ).

EVs isolated from the supernatant medium from 0. 5 to 6 h following the infection showed 3 to 5-fold higher TF activity compared to EVs isolated from MDMs treated with a control vehicle or a control pseudovirus. In additional studies, we quantified the number of EVs released from MDMs following the infection with SARS-CoV-2-SP-PV by nanoparticle tracking analysis. SARS-CoV-2-SP-PV infection increased the number of EVs released from MDMs in a time-dependent manner up to 30 min, and after that, no further increase in EVs number was observed (Supplemental Fig. 1 ). The mean diameter of EVs was 148.3 ± 30.1 nm. The fold-increase in the number of EVs was very similar to the fold-increase observed with EV-associated TF activity in SARS-CoV-2-SP-PV-infected cells (Fig. 1A) . No significant differences in EVs number between 30 min and 6 h may reflect the balance between EVs release from MDMs and the uptake of EVs by the same MDMs. Evaluation of total TF protein expression levels by immunoblot analysis (Fig. 1B) or cell surface TF expression by flow cytometry (Fig. 1C ) or immunofluorescence confocal microscopy (Fig. 1D) showed that SARS-CoV-2-SP-PV infection did not increase TF protein expression levels. Treatment of intact cells or EVs with TF antibodies fully attenuated the increased FXa generation associated with SARS-CoV-2-SP-PV infection (Fig.1E ).

Externalization of phosphatidylserine (PS) following the injury is believed to be primarily responsible for increased TF activity. 12, 18 However, annexin V pretreatment, which blocks PS-dependent increased TF activity, failed to attenuate the pseudovirus-induced TF activity (Fig.1F) . Consistent with this observation, we found no detectable increase in the binding of AF488-annexin V to the pseudovirusinfected macrophages (Fig.1G) . Taken together, these results suggest that SARS-CoV-2 infection likely to activate TF-mediated coagulation by decrypting TF and releasing TF + EVs into circulation, without inducing de novo synthesis of TF or the externalization of PS. Consistent with these data, we found that SARS-CoV-2-SP-PV infection did not increase the procoagulant activity of naïve PBMCs that do not constitutively express TF protein but enhanced the procoagulant activity of LPS-stimulated PBMCs that express TF protein (Supplemental Fig. 2 ).

Many stress indicators, including viral infections, induce translocation of ASMase from intracellular compartments onto the outer leaflet of the plasma membrane. 19 ASMase expression in MDMs treated with a control vehicle was limited primarily to the intracellular compartment ( Fig.2A , left-side images).

SARS-CoV-2-SP-PV infection mobilized ASMase from intracellular compartments to the outer leaflet of the plasma membrane ( Fig.2A , white arrowheads) without altering total ASMase protein levels (Supplemental Fig. 3 ). Cell surface SM staining with lysenin showed a marked decrease in SM in SARS-CoV-2-SP-PV-infected cells compared to cells treated with a control vehicle ( Fig. 2A, right-side images) . Fig.4) . Treatment of MDMs with ASMase functional inhibitors or ASMase silencing by siRNA curtailed the pseudovirus-induced increased TF activity on the cell surface and the release of TF + EVs (Fig.2B,2C) . Consistent with our earlier published data, 13, 14 inhibition of ASMase did not affect TF protein expression levels (Supplemental Fig.5A ).

Spike protein binds angiotensin-converting enzyme-2 (ACE-2) on host cells, which allows viral entry into cells. 20, 21 To determine whether SARS-CoV-2-SP-PV-induced ASMase activation, TF decryption, and the release of EVs require spike protein binding to ACE-2, we silenced ACE-2 expression in MDMs (Supplemental Fig.5B ). ACE-2 silencing did not affect TF protein expression (Supplemental Fig.5C,5D ) but attenuated the pseudovirus-induced increased TF activity at the cell surface as well as the release of TF + EVs (Fig.2D) . Analysis of ASMase expression by immunofluorescence confocal microscopy showed that inhibition of ACE2 attenuated the pseudovirus-induced ASMase translocation to the plasma membrane 

The authors declare no competing financial interests. and subjected to fluorescence microscopy. As a positive control, MDMs were treated with HgCl 2 (5 µg/ml) for 5 min to externalize phosphatidylserine. All experiments were repeated at least three times, and data were expressed as mean ± standard error of the mean (SEM). Statistical significance between the two groups was calculated using the Mann-Whitney test and among the groups by one-way ANOVA followed by Tukey's post-hoc analysis. *, p<0.05; **, p<0.01; ns, not statistically significant (compared to values obtained with control vehicle treatment). 

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

COVID-19 and its implications for thrombosis and anticoagulation

Tissue factor: An essential mediator of hemostasis and trigger of thrombosis

Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19

Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses

Platelet activation and platelet-monocyte aggregates formation trigger tissue factor expression in severe COVID-19 patients

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality

SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung

Regulation of tissue factor coagulant activity on cell surfaces

Sphingomyelin encrypts tissue factor: ATP-induced activation of A-SMase leads to tissue factor decryption and microvesicle shedding

Acid sphingomyelinase plays a critical role in LPS-and cytokineinduced tissue factor procoagulant activity

Secretory sphingomyelinase in health and disease

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Oxidative Stress Product, 4-Hydroxy-2-Nonenal, Induces the Release of Tissue Factor-Positive Microvesicles From Perivascular Cells Into Circulation

Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation

Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids

Structure, Function, and Evolution of Coronavirus Spike Proteins

Cell entry mechanisms of SARS-CoV-2

Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms

Infections with human rhinovirus induce the formation of distinct functional membrane domains

Induction of membrane ceramides: a novel strategy to interfere with T lymphocyte cytoskeletal reorganisation in viral immunosuppression

):100142. in the plasma membrane and using Image J software. The quantified data were shown in a graph right to the images. Right panel images: To label plasma membrane SM, fixed and nonpermeabilized cells were incubated with SM binding protein, lysenin, (1 µg/ml) for 2 h at room temperature, and then cells were incubated with rabbit anti

White arrowheads point out SM in the outer plasma membrane in control (noninfected) cells. (B) ASMase functional inhibitors attenuate SARS-CoV-2-SP-PV-induced increased TF activity in MDMs. MDMs were pretreated with ASMase inhibitors, desipramine (1 µM) or imipramine (1 µM) for 1 h, and then infected with the pseudovirus for 6 h. EVs released into the supernatant medium were isolated. TF activity on the cell surface and associated with EVs was determined by adding FVIIa (10 nM) and the substrate factor X (175 nM) and measuring the rate of factor Xa generation. (C) ASMase silencing attenuates the SARS-CoV-2-SP-PV -induced increased TF activity. MDMs were transfected with transfection reagent (vehicle), scrambled oligonucleotide (scRNA), or siRNA specific for ASMase (100 nM) using X-tremeGeneTM transfection reagent

After 48 h, the transfected MDMs were infected with the pseudovirus for 6 h, and EVs released into the supernatant medium were isolated. TF activity on cell surfaces or EVs was measured as described for panel B. (E) ACE-2 silencing blocks SARS-CoV-2-SP-PV-induced ASMase translocation to the outer leaflet of the plasma membrane. MDMs transfected with transfection reagent (vehicle), scrambled oligonucleotide (scRNA), or siRNA specific for ACE-2 (100 nM) were infected with the pseudovirus for 6 h

Cells were also immunostained for ACE-2 (magenta)

White arrowheads point out ASMase translocated to the plasma membrane in the vehicletreated or scRNA-transfected cells that were infected with the pseudovirus. The fluorescence signaling intensity of ASMase staining in the plasma membrane was quantified using Image J software. These data were shown in a graph right to the images in the bottom panel